We have been representing patients and their families in drug injury lawsuits for the past 15 years and it is our primary practice area.
Drug injury legal compensation cases involve personal injury or wrongful death claims filed on behalf of people who, unfortunately, experienced a serious side effect, had an adverse drug reaction, or died from their use of a prescription medication.
Given our many years of experience handling these types of lawsuits we know drug injury cases deserve special attention.
Drug injury claims have a personal aspect which must be appreciated and respected by the attorney handling your case. At our law firm, we do not underestimate nor lose sight of the trust which is being placed in us by clients when they select us to represent them for their lawsuit against the responsible pharmaceutical company.
We will handle your drug injury case not only competently and professionally, but with genuine care and understanding. Any inquiries from our clients are responded to promptly, and telephone calls are always returned without delay.
If you, relatives, or friends need legal advice or legal representation for a personal injury lawsuit or a wrongful death lawsuit involving a drug side effect, the Law Offices of Thomas J. Lamb is here to help.
We encourage you to submit a Drug Injury Law Case Review — it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, or some other lawyer — about your case based on his many years of experience.
We handle these drug injury cases on a contingency fee basis, meaning that there is no payment for our legal services until we are successful in getting legal compensation for you.
While our office is in Wilmington, North Carolina, we have successfully handled drug injury lawsuits for people all over the United States.
It is important to note that we do not put our clients into large class actions. Rather we favor an individual lawsuit approach, which allows us to give personal attention to each of our clients, from start to finish.
Legal & Medical News: Featured Article
As Analysis Did Not Reveal Causes Of The Increase In Death Incidents, FDA Asks Its Advisory Committee To Discuss This Safety Issue At April 2015 Meeting
SUMMARY: The AstraZeneca diabetes drugs Onglyza (saxagliptin) and Kombiglyze (saxagliptin plus metformin) will come under scrutiny at an April 14, 2015 FDA meeting according to early news reports about that upcoming event.
As regards what the FDA Briefing Material document for this Kombiglyze / Onglyza safety meeting contained and its significance, from an April 10, 2015 Bloomberg news report, “AstraZeneca’s Diabetes Drug May Raise Death Risk, FDA Says”:
AstraZeneca Plc’s type 2 diabetes drug Onglyza showed an increased risk of death in an analysis by U.S. regulators of a clinical trial on the heart effects of the treatment. Food and Drug Administration staff said their analysis of deaths in the trial suggested patients using Onglyza experienced “significant or near-significant” increases in death from all causes, not just heart problems.
We will be watching for any significant developments coming out of this April 2015 FDA Advisory Committee Meeting concerning the safety of Onglyza and Kombiglyze such as a possible label change for these AstraZeneca diabetes drugs.
- A 2004 Medical Journal Article Indicated A Possible Link Between The “Morning Sickness” Drug Use Of Zofran And Hypospadias
- In Canada, ADHD Drugs Like Adderall, Concerta, And Ritalin Are Getting New Warnings About Suicide-Related Adverse Events
- Diabetes Drugs Bydureon And Victoza: Thyroid Cancer Label Change In March 2015 Comes Without Much Notice
- YAZ / Yasmin Litigation Update For March 2015: According To Bayer’s 2014 Annual Report, “Additional lawsuits are anticipated.”
- Cardiovascular Safety Issues For Onglyza And Kombiglyze Will Be Discussed At April 2015 FDA Advisory Committee Meeting
- First 2015 Update On Fosamax Femur Fracture Litigation: Not Much New Information To Report Out
- A New Case Of Progressive Multifocal Leukoencephalopathy (PML) In A Patient Using Gilenya Is Reported By Novartis In Canada
- Various Drug Safety Issues Continue To Be Associated With Novartis Multiple Sclerosis (MS) Medication Gilenya
- Zofran Associated With Birth Defects When Used During Pregnancy As An “Off-Label” Morning Sickness Treatment
- Viagra / Cialis / Levitra: Prostate Cancer Recurrence When Used After Radical Prostatectomy Surgery
- UK Drug Safety Regulator Issues New Warnings About The Use Of Depakote / Depacon / Depakene By Women During Pregnancy
- Pancreatic Cancer As A Side Effect Of Diabetes Drugs Bydureon, Byetta, Januvia, And Victoza